Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GLMD. StockNews.com began coverage on shares of Galmed Pharmaceuticals in a research report on Tuesday. They set a "sell" rating for the company. Maxim Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday. Raymond James lowered shares of Galmed Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 18th. Cantor Fitzgerald lowered shares of Galmed Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research report on Thursday, August 4th. Finally, HC Wainwright lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Tuesday, May 3rd. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $5.00.

Galmed Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:GLMD opened at $0.45 on Tuesday. Galmed Pharmaceuticals has a 52-week low of $0.38 and a 52-week high of $3.39. The firm has a fifty day moving average of $0.54 and a 200 day moving average of $1.06. The company has a current ratio of 8.48, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01.

Galmed Pharmaceuticals (NASDAQ:GLMD - Get Rating) last announced its earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.09. Sell-side analysts forecast that Galmed Pharmaceuticals will post -0.85 EPS for the current fiscal year.